News Releases

 
News Releases
  Date Title and Summary View
Aug 8, 2017
-- Pivotal Phase III ADVOCATE trial of avacopan on track to complete enrollment in mid-2018 as projected -- -- Launching second trial of avacopan in patients with C3 Glomerulopathy (C3G) -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN VIEW, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a b...
Jul 26, 2017
MOUNTAIN VIEW, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, today announced that the Company's second quarter 2017 financial results will be released after market close on Tuesday, August 8, 2017. Che...
Jun 6, 2017
-- Clinical Study Shows Drop in Proteinuria in Patients Treated with Avacopan for IgA Nephropathy (IgAN) -- -- Potential of CCR2 Inhibitor as a Therapeutic Treatment Option for FSGS Validated -- MOUNTAIN VIEW, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications ...
May 24, 2017
MOUNTAIN VIEW, Calif., May 24, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences: ...
May 23, 2017
MOUNTAIN VIEW, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the European Medicines Agency (EMA) has granted orphan medicinal product designation for avacopan (formerly CCX168) in t...
May 10, 2017
-- Phase III clinical trial of avacopan for the treatment of ANCA Vasculitis underway as Journal of American Society of Nephrology (JASN) publishes results of successful Phase II CLEAR clinical trial -- -- Received FDA Orphan Drug Designation for avacopan in the treatment of C3 Glomerulopathy (C3G) -- -- Conference call today at 5:00 p.m. Eas...
Apr 27, 2017
MOUNTAIN VIEW, Calif., April 27, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's first quarter 2017 financial results will be released after market close on Wednesday, May 10, 2017. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on Wednesday, May 10,...
Mar 22, 2017
MOUNTAIN VIEW, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for avacopan in the treatment of patie...
Mar 14, 2017
-- Expanded Vifor Pharma partnership now totals $155 million in upfront cash commitments, $1.2 billion in potential milestone payments, plus substantial royalties on potential net sales -- -- Initiated Phase III clinical trial of Avacopan for the treatment of ANCA Vasculitis -- -- Conference call today at 5:00 p.m. Eastern Time -- MOUNTAIN V...
Mar 1, 2017
MOUNTAIN VIEW, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the Company's fourth quarter 2016 financial results will be released after market close on Tuesday, March 14, 2017. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 14, 2017 to...
Page:
1
... NextLast
= add release to Briefcase